arrow
L

Liping Liu

Hunan Cancer Hospital
H指数:34
被引数:4,140

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study

BEBT-209,一种主要CDK4选择性抑制剂,用于治疗HR+/HER2-晚期乳腺癌(BECTOP1):一项1期、多中心、开放标签研究

2025-07-190
PREAI
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
2024-10-010
OAAI
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial

Pyrotinib联合来曲唑治疗激素受体阳性、人表皮生长因子受体2阳性转移性乳腺癌 (PLEHERM): 一项多中心、单臂、II期临床试验

2023-06-266
OAAI
The Herb Pair Radix Rehmanniae and Cornus Officinalis Attenuated Testicular Damage in Mice With Diabetes Mellitus Through Butyric Acid/Glucagon-Like Peptide-1/Glucagon-Like Peptide-1 Receptor Pathway Mediated by Gut Microbiota

中药地黄和山茱萸通过肠道菌群介导的丁酸/胰高血糖素样肽-1受体途径减轻糖尿病小鼠睾丸损伤

2022-02-2211
OAAI